Biodexa Pharmaceuticals Secures U.S. Patent for eRapa, Plans Phase 3 Study

The latest announcement is out from Biodexa Pharmaceuticals ( (BDRX) ).

Biodexa Pharmaceuticals announced that the U.S. Patent and Trademark Office has allowed a patent for their oral rapamycin nanoparticle preparation, eRapa, which is set to issue on March 4, 2025. This patent provides additional exclusivity for eRapa, which has already received orphan drug designation from the FDA for Familial Adenomatous Polyposis (FAP), granting seven years of market exclusivity upon approval. The company plans to begin a Phase 3 registrational study in the next quarter, funded by a $17 million grant from the Cancer Prevention Research Institute of Texas, matched by Biodexa’s $8.5 million contribution. This development is expected to enhance Biodexa’s market position by strengthening its intellectual property portfolio and advancing its clinical programs.

More about Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for the treatment of diseases with unmet medical needs. Their lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer indications. The company is supported by proprietary drug delivery technologies aimed at improving the bio-delivery and bio-distribution of medicines, with headquarters and R&D facilities in Cardiff, UK.

YTD Price Performance: -9.29%

Average Trading Volume: 453,628

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $2.48M

Learn more about BDRX stock on TipRanks’ Stock Analysis page.